Introduction
============

This electroencephalographic (EEG)-based research project aimed to advance our neural understanding of language processing by assessing the effects of ketamine-induced *N*-methyl-[D]{.smallcaps}-aspartate (NMDA) receptor hypofunction on mismatch negativity (MMN) responses to changes in speech stimuli (i.e., speech deviants). We also investigated stimulus-locked time-frequency and event-related spectral perturbation (ERSP) signatures of ketamine-induced changes in speech MMNs. Although frequently assessed in relation to high frequency (beta and gamma) oscillations ([@B82]), we specifically focused on the evoked and phase-locking activity of the theta band as viable translational biomarkers for investigating brain dynamics underlying language processing deficits, and their treatment with NMDA receptor antagonists. To examine ketamine effects on speech processing at the oscillatory and network level, we combined ERP and ERSP approaches with a source localization technique, using low-resolution brain electromagnetic tomography (LORETA) to assess MMN-associated current density in auditory and language related regions of interest. Addressing the clinical relevance of this work, as multiple lines of evidence have implicated NMDA receptor dysfunction in schizophrenia pathophysiology including impairments in MMN generation, this study examined the relationship of these neural measures to psychotomimetic symptoms produced by acute ketamine administration. This is the first known human EEG study combining sensor- and source-level approaches to assess the neural substrates of speech deviance detection modified by NMDA receptor antagonist treatment and their association with schizophrenia-like symptomatology.

Background
==========

Event-Related Potentials (ERP)
------------------------------

Neurophysiological approaches such as EEG-derived averaged event-related potentials (ERP) are used increasingly as biomarkers for aiding our understanding the neural mechanisms underlying normal and abnormal information processing, and to monitor novel drug therapies for treatment of sensory and cognitive processing deficits ([@B54]; [@B6]; [@B51]). Within the auditory system, sensory processing is reflected in the generation of the MMN, an ERP reflecting the function of the auditory "echoic" memory system, which maintains brief representations of auditory stimulus features. This automatic change-detection response is elicited when the brain detects an infrequent deviance in a stream of sound stimulation, even in the absence of attention ([@B97]; [@B99]; [@B107]). The MMN is most commonly recorded in the context of the basic "oddball paradigm" where a physically constant "standard" tone is infrequently replaced by a "deviant" tone (e.g., differing in frequency, duration or intensity). The MMN elicited by the deviance is best observed in the deviant-minus-standard ERP as a frontocentrally distributed negativity, typically peaking at 150--200 ms after the onset of deviant stimulus. As MMN and its abnormality can also be elicited by changes of an abstract nature such as a violation of a multi-stimulus pattern or regularity ([@B4]; [@B120]), or that of a complex sequential stimulus rule, the MMN is thought to signal a *prediction-error* based on regularity-violation rather than just stimulus-change ([@B133]).

*N*-Methyl-[D]{.smallcaps}-Aspartate (NMDA) Receptor Function
-------------------------------------------------------------

*N*-methyl-[D]{.smallcaps}-aspartate receptors are widely expressed in sensory and higher cognitive brain regions, and dose-dependent MMN deficits are observed with either systemic or local infusion of NMDA receptor antagonists directly into the auditory cortex ([@B55]; [@B48]). Evidence in animal models of the role of NMDA receptor hypofunction, either genetic ([@B23]) or pharmacologically induced, on aberrant MMN generation ([@B40]) is paralleled by studies in healthy human volunteers administered acute sub-anesthetic doses of ketamine. Ketamine is a non-competitive NMDA receptor antagonist which reduces and delays MMN generation elicited by frequency and duration tone deviants ([@B118]). MMN generation is not modulated either by dopamine (D1/D2) agonists or by psychotomimetics targeting serotonin (5-HT2H) receptors ([@B6]; [@B62]). Suggesting both limited dopaminergic involvement and relative specificity of NMDA receptor antagonist effects, MMN is considered to be a simple and useful biomarker of NMDA receptor-type glutamate dysfunction ([@B3]).

Mismatch negativity has been increasingly used for studying hierarchical levels of acoustic processing involved in speech and language function. General findings of larger MMNs to speech sounds and words compared with unfamiliar sounds and pseudo-words, respectively, suggests that MMN can serve as a reliable probe of phonological, lexical, semantic, and syntactic processes ([@B96]; [@B114]; [@B123]). Our primary objective was to assess the effects of ketamine-induced NMDA receptor hypofunction on speech MMNs, assessing MMN response to ketamine as a function of 5 speech deviants, including changes in syllable frequency, syllable intensity, vowel duration, as well as consonant change and across-vowel changes. Accurate perception of acoustic features of spoken words (e.g., frequency and intensity) and their temporal attributes (e.g., duration or determining where a work, phrase, and sentence ends) are essential for affective social communication and there is evidence that neural processing of phonological features differs from that of non-linguistic auditory information ([@B96]; [@B114]; [@B123]). As meta-analyses of studies examining MMN response to ketamine have shown equivalent reductions in duration and frequency MMNs, we also expect that ketamine will impair MMN generation across deviant types.

ERO Time-Frequency Analysis
---------------------------

A mechanistic understanding of the effects of NMDA receptor function on MMN requires an evaluation of its impact on event-related spectral oscillatory (ERO) activity across different frequency bands \[delta (\<4 Hz), theta (4--8 Hz), alpha (8--12 Hz), beta (12--30 Hz), gamma (30--80 Hz)\]. EROs can be obtained at levels ranging from single cell to focal field potentials in animals, to large-scale synchronized activities measured at the human scalp ([@B93]). Power in the theta band is particularly prominent during the processing of tone and speech deviants, with studies showing that neural generation of the MMN is accompanied by theta power modulation and theta phase alignment ([@B27]; [@B46]; [@B7]; [@B73]; [@B13]; [@B41]; [@B75]; [@B14]). NMDA receptor antagonists modulate background spontaneous theta oscillations ([@B81]; [@B47]) and reduce both MMN and the theta response to auditory deviants in rodents ([@B82]). Thus, evoked theta activity is proposed as a viable translational biomarker for investigating brain dynamics underlying auditory processing deficits and their treatment with NMDA receptor antagonists. In addition to measuring the power of oscillations associated with the averaged time-domain ERPs, sensitive 'time-frequency' analyses of trial-by-trial ERSPs are being increasingly used to provide a more detailed picture of brain dynamics underlying ERPs, which is not available with the averaged time-domain ERP, as seen with the MMN waveform ([@B83]). One of the most frequently used ERSP measures, which is computed on a trial-by-trial basis and is known to independently (vs. power) affect the amplitude of the averaged ERP, is the phase locking factor \[PLF; also known as phase locking index (PLI), or inter-trial phase coherence (ITC)\]. This measures the degree of phase consistency across trials, and is commonly interpreted to reflect phase resetting of ongoing oscillations. The frontal MMN has been found to be associated with an increase in theta power for deviant stimuli as well as by theta phase alignment, whereas the temporal MMN has been found to be associated with theta phase resetting with no power modulation ([@B27]). This study investigated the time-frequency signature of ketamine-induced changes in speech MMNs with a specific focus on evoked theta power and theta phase locking.

ERP Source Activity
-------------------

The neural characteristics of the MMN (amplitude, power, and phase resetting) are presumed to result from activity of neural networks involved in its generation ([@B27]). Studies employing dynamic causal modeling, source localization, functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) have shown the MMN to be generated by neural activity and connectivity within a hierarchically organized cortical network involving temporal (bilateral auditory cortex) and predominantly right frontal brain regions ([@B97]; [@B99]). In addition to primary (pAC) and secondary (sAC) auditory cortices in the temporal lobe, the inferior frontal gyrus (IFG) is the most studied non-auditory cortical contributor to MMN generation and appears to serve as an evaluator of stimulus relevance ([@B136]). In the oddball paradigm, its activity may reflect the importance of the violated expectation (prediction error) detected by auditory cortical areas ([@B136]). Activity within and between cortical areas is essential for auditory perception and oscillatory activity plays a cardinal role in the recruitment of brain regions and their coupling ([@B83]). Neurons within the IFG, such as those located in Broca's language area and Broca's right homolog, are characterized by a well-described theta frequency synchronization with the auditory cortex ([@B46]; [@B13]). In order to examine ketamine effects on speech processing at the sensory and network levels, we combined ERP and time-frequency/ERSP approaches with a source localization technique, using low-resolution brain electromagnetic tomography (LORETA), a 3D inverse solution, to assess intracerebral current density as a measure of activation of regions of interest (ROI: pAC, sAC, and IFG) during MMN generation. With ERPs and their underlying spectrally analyzed activity, we expected to see ketamine-induced reductions in MMN amplitude, evoked theta power and theta phase resetting (phase-locking), while with source analysis, we predicted reduced current density (activation) in temporal and frontal cortical areas.

Relevance for Schizophrenia
---------------------------

For a number of reasons, this line of research has potential clinical implications for schizophrenia cognition ([@B37]; [@B49],[@B50]; [@B86]; [@B52]; [@B56]) and particularly with respect to improving our understanding of low-level acoustic processing involved in speech and language functions that are distinctively impaired in schizophrenia ([@B116]; [@B10]). Among these reasons are: a vast neuroimaging, molecular, and genetic literature supporting a glutamate hypothesis of schizophrenia involving NMDA receptor hypofunction ([@B11]; [@B15]; [@B57]; [@B91]; [@B92]); pharmacological modeling of schizophrenia features, including clinical, cognitive, and sensory deficit symptoms in rodents/healthy humans with acute sub-anesthetic doses of the NMDA receptor antagonist ketamine ([@B112]; [@B130]); findings in schizophrenia of reliable and robust attenuation of the MMN (effect size *d* ∼ 1.00), which is not affected by antipsychotics ([@B98]), is more apparent with speech MMNs ([@B64]; [@B24]) and is associated with reductions in frontotemporal volume/function ([@B64]; [@B63]; [@B147]) and diminished theta responses to auditory deviants ([@B117]; [@B44]; [@B65]; [@B70]; [@B83]). As reduced MMNs predict conversion to psychosis in clinical high risk and reflect a vulnerability to disease progression ([@B101]), and as smaller MMNs to tone deviants are associated with greater vulnerability to NMDA receptor system disruption with ketamine in healthy humans (i.e., they experience greater psychosis-like symptoms; [@B139]) a secondary objective of this study is to examine the relationship between baseline (placebo) frontal speech MMN/oscillatory and source activity and subjective psychotomimetic response to ketamine.

Materials and Methods {#s1}
=====================

Experimental Subjects
---------------------

Twenty healthy, medication-free, non-smoking, right-handed males (age = 20.94, *SD* = 2.44) were recruited through city/university newspaper advertisements. Only males were recruited in order to avoid potential confounding effects of hormonal variations associated with the menstrual cycle in females. Only non-smokers were sampled in order to reduce any potential confounding effects of nicotine and/or nicotine withdrawal symptoms on ketamine response. Following data processing, two of the participants exhibited marked artifact contamination in their EEGs and the final study sample was limited to *N* = 18. Participants were initially screened by telephone for non-smoker status (defined as not smoking a lifetime total of \>100 cigarettes, with no smoking in the past 12 months), absence of medical illnesses, as well as psychiatric and alcohol/drug dependence disorders. They were then assessed for psychopathology and personal/family psychiatric history during an in-person screening session using the Structured Clinical Interview (SCID-non-patient version; [@B144]) for DSM-IV and the Family Interview for Genetic Studies (FIGS; [@B89]). They also underwent a full medical examination (including ECG), laboratory blood testing (to rule out any significant medical conditions), urine toxicology (to screen for psychoactive substances), an expired air carbon monoxide test to confirm non-smoker status \[\<3 parts per million (ppm)\], and auditory threshold testing to ensure normal hearing.

Any participants with a current/past or family history of an axis 1--2 DSM-IV disorder, abnormal blood/ECG results, positive drug screen (for barbiturates, ketamine, cocaine, benzodiazepines, ethanol, cannabinoids, and opioids), significant medical illnesses \[including seizures and recent (\<6 months) head trauma with loss of consciousness\], or audiometric assessed indication of abnormal hearing (hearing threshold above 30 dB SPL for 1,000 Hz pure tone) were excluded. The study was limited to males to avoid possible variations related to menstrual cycle. All participants provided written informed consent during the in-person screening session and were compensated \$75 CAD per test session. This study was approved by the Research Ethics Board of the Royal Ottawa Health Care Group and was conducted in accordance with the Tri-Council Policy Statement on Ethical Conduct for Research Involving Humans.

Study Design
------------

Participants were assessed within a randomized, double-blind design consisting of two test sessions separated by a minimum of 5 days. Half received the placebo (saline) in their first test session and ketamine in their second test session, while the other half received the treatments in the reverse order.

Drug Administration
-------------------

A racemic ketamine or NaCl 0.90% w/v bolus dose was administered over 10 min (0.26 mg/kg), followed immediately by a constant infusion lasting 60 min (0.65 mg/kg), using an Imed Gemini PC-1 pump. The ketamine dose is consistent with previous studies ([@B77]; [@B94]; [@B81]; [@B65]).

Study Procedures
----------------

Test sessions occurred in the morning (beginning at 8:00 a.m.), following overnight abstinence from caffeine, food, drinks (except for water), and alcohol. Sessions began with the insertion of an antecubital intravenous line, attachment of a 2-lead ECG (for continuous safety monitoring), and electrode positioning, followed by the administration of the bolus dose and constant infusion. After a 10 min stabilization period (i.e., 10 min into the infusion), EEG recording and auditory MMN paradigm administration began. This was followed by an evaluation with the Clinician Administered Dissociative States Scale (CADSS; [@B8]), which is composed of 19 self-report items (0 = not at all; 1 = slightly; 2 = moderately; 3 = considerably; 4 = extremely) and yields three subjective sub-scale scores (amnesia, depersonalization, and derealization) as well as 8 clinician rated items which yields an "observer" sub-scale score. Vital signs and adverse events were analyzed for safety purposes only. Participants remained in the lab until all symptoms had ceased and were not allowed to drive vehicles to or from the test sessions.

MMN Paradigm
------------

During MMN paradigm administration, participants viewed a silent video (The Blue Planet by [@B9]) while stimuli were presented binaurally through noise-canceling headphones. A fast multi-feature speech paradigm ([@B108]) was employed to acquire MMNs to phonetic and acoustic changes in speech stimuli. Compared to standard oddball paradigms, which allow for assessment of cortical discrimination of 1--2 sounds features, multi-feature MMN paradigms allow for very fast assessment of extensive auditory discrimination profiles, evaluating central auditory discrimination of multiple auditory attributes ([@B100]). The stimuli consisted of semi-synthetic Finnish-language consonant-vowel (CV) syllables. The standard stimuli were /te:/ and /pi:/ (frequency = 101 Hz, intensity = 70 dB, syllable duration = 170 ms). The deviant stimuli differed from the standards either in syllable FREQUENCY (FO ±8%; 93/109 Hz), syllable INTENSITY (±6 dB), VOWEL-DURATION (-70 ms; 100 ms /te/ and /pi/), CONSONANT (/pe:/ and /ti:/), or VOWEL (/ti:/ and /pe:/). Additional details regarding the creation of these stimuli can be found in [@B108]. The presentation of these stimuli followed the same sequence as previously outlined ([@B100]): every other syllable was a standard (*P* = 0.5) and every other one of the 5 deviant syllables (*P* = 0.1 each). There were four 5-min sequences including 465 syllables, of which the first 5 were always standards. In two of the sequences the standard syllable was /te:/ and the deviants were FREQUENCY /te:/, INTENSITY /te:/, VOWEL DURATION /te/, CONSONANT /pe:/, and VOWEL /ti:/, whereas in the other two sequences the standard was /pi:/, and the deviants were FREQUENCY /pi:/, INTENSITY /pi:/, VOWEL DURATION /pi/, CONSTONANT /ti:/, and VOWEL /pe:/. The occurrence of the deviants were pseudo-randomized in a way that all 5 deviants appeared once in an array of 10 successive stimuli and the same deviant was never repeated after the standard following it. The order of the two sequences was randomized between participants. Each deviant type was presented 184 times, the stimulus-onset asynchrony (SOA, onset to onset) was 650 ms, and the total recording time was 20 min. Although use of a native (English) speech paradigm may have been preferable with our English speaking sample, this was the only published 'optimal' paradigm that allowed for quick, efficient assessment of multiple speech deviant types in a single recording when we initiated our study. The five speech deviations are generally relevant features in speech sounds across most, if not all, spoken languages. The use of a non-native paradigm to derive automatic cortical discrimination profiles has the advantage of reducing the potential confounding influence of higher-order semantic processes (on MMN generation), which are known to interact with emotional processes that are markedly impaired in schizophrenia as reflected by MMN-indexed auditory emotion recognition deficits ([@B61]).

ERP Recording
-------------

Electroencephalographic activity was recorded using current pharmaco-EEG standards ([@B71]; [@B119]; [@B58]). This involved the use of a cap (EasyCap, Herrsching-Breitbrunn, Germany) embedded with 30 Ag^+^/Ag^+^Cl^-^ electrodes, left and right mastoids (TP9 and TP10), as well as 2 bipolar electrodes placed on the supra- and sub-orbital ridge and external canthi (to measure vertical and horizontal electro-oculographic activity). An electrode on the nose served as the reference and a ground electrode was positioned at AFz. Electrical recordings were carried out using a Brain Vision QuickAmp^®^ (Brain Products GmbH, Munich, Germany) amplifier and Brain Vision Recorder^®^ (Brain Products GmbH, Munich, Germany) software. Electrical activity was sampled at 500 Hz, with amplifier bandpass filters set at 0.1--100.0 Hz. Electrode impedances were \<5 kΩ.

MMN Processing
--------------

Mismatch negativity analysis was completed using Brain Vision^®^ Analyzer 2 software (Brain Products, Munich, Germany). Offline pre-processing involved a visual inspection of the recordings for contamination due to noticeable ocular/muscle/cardiac activity and/or drowsiness, digital filtering at 1--20 Hz, ocular correction with an algorithm ([@B36]), segmentation (-100 to 400 ms), semi-automatic artifact rejection (±100 μV), and baseline correction (relative to the pre-stimulus segment). The remaining epochs (minimum 100 per deviant) were then averaged based on stimulus type, and subtraction waveforms were computed (deviant -- standard) by digital point-by-point subtraction of standard waveform voltage values from each deviant waveform values. For the purposes of our study and based on grand average waveforms, frontal MMN at Fz, F3 and F4 scalp sites was quantified in terms of peak amplitude (maximum negative voltage relative to average pre-stimulus voltage within the 120--250 ms window for frequency, intensity, duration, vowel, deviants and the 150--280 ms window for consonant deviants). MMN latency (relative to stimulus onset) for each of the deviants, was quantified only at the mid-frontal (Fz) site. The mean number of epochs (±S.E.) for MMN averages was not significantly different between deviants, nor were there differences in epoch numbers across placebo (frequency = 172.67 ± 2.55; intensity = 171.72 ± 2.57; consonant = 170.78 ± 3.02; vowel duration = 171.22 ± 2.68; across vowel = 171.33 ± 2.78) and ketamine conditions (frequency = 174.00 ± 1.77; intensity = 174.78 ± 1.85; consonant = 173.89 ± 1.95; vowel duration = 173.83 ± 1.99; across vowel = 174.72 ± 1.65). In contrast to the original study employing the fast multi-feature Finnish speech paradigm ([@B100]), which employed a mastoid reference and thus evidenced no MMN generation at temporal/posterior sites, our use of a nose reference yielded prominent polarity-inverted MMN responses in these regions, which results from the dipole generator orienting between the auditory and frontal cortices. As a secondary analysis, MMNs were also measured and analyzed at left (TP9) and right (TP10) mastoid sites. Amplitude of the obligatory N1 component (peak negativity between 90 and 120 ms) elicited by the standard stimulus was also measured in order to clarify whether or not ketamine effects were specific to deviance processing vs. general sensory processing. [Figure 1](#F1){ref-type="fig"} displays the placebo grand averaged difference waveforms \[including the polarity reversed MMNs and mastoid (TP9, TP10) sites\] for the five speech deviants, together with the grand averaged topographic maps showing amplitude distribution of MMNs across recording sites.

![Grand averaged ERP difference waveforms elicited in response to 5 speech deviants in the placebo condition.](fphar-10-00455-g001){#F1}

ERO and ERSP Processing
-----------------------

For each deviant type, the average frontal ERO was obtained for the theta band at Fz, F3, and F4 sites in a manner similar to that of [@B39]. Time-varying spectral activity (μV) was computed on averaged epochs (separately for each deviant) using a complex Morlet wavelet with a constant \[c = σ~f~/f, where σ~f~ = the standard deviation of the centre frequency (f)\] value of 5; this was computed over the range of 1--20 Hz with 40 frequency steps. Evoked theta activity (3--7 Hz) within time-frequency ROIs were exported for analysis (±50 ms around peak MMN amplitude). ERO values were then ln-transformed to ensure that the data were normally distributed for statistical analysis. Using the same methodology, theta ERO (within the MMN latency range) was quantified for the standard stimulus to determine whether ketamine effects were specific to deviance processing or generalized to all sensory processing. As background, ongoing oscillations may moderate stimulus-induced oscillatory response, an additional analysis was conducted to assess potential changes in spontaneous theta with ketamine administration. Pre-stimulus epochs of 100 ms duration were digitally sampled (500 Hz) across standard and deviant stimuli and submitted to Fast Fourier Transform (FFT) analysis for computation of ln-transformed spectral amplitude in the theta (3--7) band in the MMN latency range. Values across epochs were summed for statistical analysis.

Phase-locking factor (PLF) values were computed by first performing wavelet transformation on each epoch, and subtracting the standard epochs from the deviants. By using the BrainVision Analyzer "Phase Locking Factor" solution, the average time-frequency PLF values can be extracted. PLF was calculated as 1 minus the circular variance of phases, as described by [@B127], and ranges from 0 (random distribution of phases) to 1 (perfect phase locking). Similarly to the ERO data, theta PLF (3--7 Hz) within time-frequency regions of interest was exported for analysis (±50 ms around peak MMN amplitude). PLF was also quantified for the standard stimulus and for spontaneous (pre-stimulus) activity.

Brodmann Area Regions of Interest
---------------------------------

Intracortical current density (A/m^2^) measured at peak MMN activity (based on ERP grand averages) from predefined ROIs were computed using exact low resolution electromagnetic tomography (eLORETA, version 2081104; [@B110]; [@B111]). eLORETA models the cortex as a collection of voxels (6239 voxels with a spatial resolution of 7 mm). Relying on the digitized Talairach atlas and the average MRI brain provided by the Montreal Neurological Institute (MNI) and a cortically restrained solution space, it calculates the non-unique "inverse" problem by computing a three dimensional distribution of intracortical source activity (with zero location error) at each voxel based on surface-level electrical signals. The original LORETA method has received considerable validation from studies using more established localization methods such as structural and functional MRI, PET, and implanted electrode recordings. The selected ROIs were based on eLORETA-defined Brodmann Areas (BA), and current density data from a single centroid representative voxel of each BA (the voxel closest to the center of the BA mass, which is an excellent representation of the corresponding BA) were extracted for further analysis. This included the primary (BA 41) and secondary (BA 42) auditory cortices and the three regions comprising the IFG (BAs 44, 45, and 47). Current density was derived for the left and right hemispheres of each BA.

Statistical Analyses
--------------------

Statistical analysis was conducted using SPSS version 23 (SPSS Inc., Chicago, IL, United States). Separate repeated measures analysis of variances (rmANOVA) for each EEG measure were carried out. The ERP amplitude, theta ERO, and theta PLF ANOVAs consisted of three within-group factors, including drug (placebo and ketamine), deviant type (frequency, intensity, vowel duration, across vowel, and consonant) and electrode site \[left (F3), central (Fz), and right (F4)\]. A similar but secondary set of analyses, limited to ERP amplitude, were conducted using responses derived at left (TP9) and right (TP10) temporal electrode sites. MMN latency (at Fz only) was analyzed with similar ANOVAs but with no site factor, while latency at temporal sites was analyzed at left and right hemispheres. Finally, for ERPs, the N100 amplitude/latency values derived from the standard stimulus were also subjected to similar rmANOVA with drug and electrode site (Fz, F3, and F4) as factors. The eLORETA-derived current density values were also analyzed using a rmANOVA and involved two within-group factors, including drug (placebo and ketamine) and ROI (BA41, BA42, BA44, BA45, and BA47). Significant (Greenhouse-Geisser corrected when appropriate) effects were followed up with Bonferroni-adjusted comparisons. The CADSS subscales exhibited non-normal distributions and were analyzed using the non-parametric Wilcoxon Signed Ranks Test (WSRT).

Spearman's rho correlations were used to examine the relationship between baseline (placebo) electrophysiological measures (ERP, ERO, PLF, and BA current density) with changes in dissociate/perceptual symptoms \[difference scores (ketamine -- placebo) as for the CADSS sub-scales\]. For ERPs (MMN), correlations were only conducted with the frontal midline recording site (Fz) and only correlations equal/less than *P* \< 0.01 were considered significant in order to reduce likelihood of chance findings associated with multiple testing.

Results
=======

CADSS Symptom Ratings
---------------------

[Figure 2](#F2){ref-type="fig"} displays the mean (±SE) rating scores for the placebo and ketamine conditions. Relative to placebo, ketamine increased observer rated symptom scores (WSRT = -3.40, *p* \< 0.001) and for self-ratings, depersonalization (WSRT = -3.30, *p* \< 0.001), derealization (WSRT = -3.52, *p* \< 0.0001), and amnesia scores (WSRT = -3.31, *p* \< 0.001) were significantly higher with ketamine than with placebo.

![Mean (±SE) Clinician Administered Dissociated States Scale (CADSS) values for the placebo and ketamine conditions. ^∗^*p* \< 0.001.](fphar-10-00455-g002){#F2}

MMN Amplitude/Latency
---------------------

Mid-frontal (Fz) grand averaged deviant-minus-standard difference waveforms for each deviant type in the multi-feature speech paradigm presented in placebo and ketamine conditions are shown in [Figure 3](#F3){ref-type="fig"}. Significant main effects were observed for the drug condition across all linguistic sound features (*F* = 24.29, df = 1/17, *p* \< 0.0001), with ketamine reducing MMN in response to changes in syllable frequency, syllable intensity, vowel-duration, consonant change, as well as vowel change. Drug did not interact with deviant type or electrode site, but follow-up of a significant deviant effect (*F* = 18.17, df = 4/68, *p* \< 0.0001) found largest MMNs with frequency, vowel duration and across vowel deviants, which showed similar amplitudes, each of which was greater than intensity (*p* = 0.01), with the latter deviant producing the smallest of the MMNs. For the significant electrode site effect (*F* = 8.39, df = 2/34, *p* \< 0.001), MMN amplitude at frontal midline (Fz) was greater than both left (F3) and right (F4) frontal MMNs (*p* \< 0.05), which exhibited similar amplitudes. Frontal MMN latency was not altered by ketamine.

![**(A)** Grand averaged ERP waveforms at Fz and topographic maps generated in response to 5 speech deviants during placebo and ketamine conditions. **(B)** Mean (±SE) peak frontal amplitudes (μV) for the placebo and ketamine conditions. ^∗^*p* \< 0.05.](fphar-10-00455-g003){#F3}

Left (TP9) and right (TP10) temporal grand averaged deviant-minus standard waveforms for each deviant type recorded during placebo and ketamine conditions are shown in [Figure 4](#F4){ref-type="fig"}. Although not interacting with deviant type or electrode site, a significant drug effect (*F* = 6.17, df = 1/17, *p* \< 0.03) showed reduced MMN amplitudes with ketamine vs. placebo administration, particularly at TP9 sites. For the significant deviant type effect (*F* = 10.19, df = 4/68, *p* \< 0.0001), the largest MMNs were equivalently elicited by intensity, frequency and across vowel deviants. Compared to all deviant types, the consonant deviant elicited the smallest MMN (*p* \< 0.001). MMN elicited by the duration deviant was similar to the MMN elicited by the frequency deviant but smaller than the intensity (*p* \< 0.04) and vowel duration (*p* \< 0.007) MMN. Temporal MMN latencies were not affected by ketamine.

![**(A)** Grand averaged ERP waveforms at mastoid sites (TP9 and TP10) generated in response to 5 speech deviants during placebo and ketamine conditions. **(B)** Mean (±SE) peak temporal amplitudes (μV) for the placebo and ketamine conditions. ^∗^*p* \< 0.05.](fphar-10-00455-g004){#F4}

N1 amplitude/latency derived from the standard stimulus ERP frontal (Fz) recording sites were not altered by ketamine administration (*F* = 0.76, df = 1/17, *p* = 0.79).

Evoked Theta Power
------------------

[Figure 5](#F5){ref-type="fig"} shows the grand averaged evoked (stimulus-locked) time-frequency responses to each speech deviant type during placebo and ketamine administration sessions. Significant main drug effects were exhibited (*F* = 21.99, df = 1/17, *p* \< 0.0001), but follow-up tests showed evoked theta power for frequency, intensity and vowel deviants being reduced by ketamine compared to placebo administration. Although not interacting with deviant type, follow-up of a significant deviant effect (*F* = 9.35, df = 4/68, *p* \< 0.001) found greater evoked power at midline (Fz) compared to both left (F3) and right (F4) sites (*p* \< 0.007). Evoked theta power elicited by the standard stimulus was not affected by ketamine. Ketamine administration did not alter ongoing spontaneous theta power derived from frontal recording sites.

![**(A)** Grand averaged time frequency plots showing theta power response at the frontal midline (Fz) site to 5 speech deviants during placebo and ketamine conditions. **(B)** Mean (±SE) frontal theta evoked activity (μV) for the placebo and ketamine conditions. ^∗^*p* \< 0.05. † = at Fz only.](fphar-10-00455-g005){#F5}

Phase Locking Factor
--------------------

Grand averaged PLF for each speech deviant type during placebo and ketamine conditions are shown in [Figure 6](#F6){ref-type="fig"}. Significant overall drug effects were observed (*F* = 9.63, df = 4/68, *p* \< 0.0001) with ketamine (vs. placebo) significantly diminishing PLF in relation to frequency and intensity deviant types. A significant deviant effect (*F* = 8.13, df = 4/68, *p* \< 0.0001) showed consonant PLF to be smaller compared to PLFs associated with other deviants (*p* \< 0.02). Electrode site differences were also shown (*F* = 3.49, df = 2/34, *p* \< 0.05), with greater PLF being observed at frontal midline (Fz) site compared to left (F3) and right (F4) frontal sites (*p* \< 0.007). Theta evoked power elicited by the standard stimuli was not influenced by ketamine, nor was PLF derived from spontaneous (pre-stimulus) activity affected by ketamine.

![**(A)** Grand averaged event-related spectral perturbation (ERSP) responses highlighting theta phase locking factor changes at the frontal midline (Fz) site to 5 speech deviants in placebo and ketamine conditions. **(B)** Mean (±SE) frontal phase locking factor for the placebo and ketamine conditions.](fphar-10-00455-g006){#F6}

Source Current Density
----------------------

Mean (±SE) ROI current density values for auditory and frontal cortices during placebo and ketamine conditions are displayed in [Figure 7](#F7){ref-type="fig"}. With the exception of consonant and vowel change deviants, current density across all deviants and ROIs were significantly altered by drug administration (*F* = 13.03, df = 1/17, *p* \< 0.002), with ketamine reducing current density vs. placebo. Only the pAC and sAC regions failed to respond to ketamine during the processing of frequency deviants. Regions varied in current density (*F* = 16.94, df = 4/68, *p* \< 0.0001), with the highest current density being observed in the IFG (BA47) compared to other regions (*p* \< 0.003) and the lowest density was in the pAC.

![Mean (±SE) ln-transformed source-localized CSD values (A/m^2^) of Brodmann Area (BA) regions of interest associated with 5 speech deviants during placebo and ketamine conditions. ^∗^*p* \< 0.05 (IFG^44^ = BA44; IFG = BA45; IFG^47^ = BA47; † = right hemisphere effect).](fphar-10-00455-g007){#F7}

In a significant deviant effect (*F* = 3.19, df = 4/68, *p* \< 0.02), consonant change produced the lowest current density compared to other deviants (*p* \< 0.02) and, although similar to vowel duration and syllable intensity/frequency deviant current densities, the across vowel deviant exhibits the highest current density values. Follow-up of a significant deviance x region interaction (*F* = 4.02, df = 16/272, *p* \< 0.0001), found that the comparatively lower consonant (vs. other deviants) current density was limited to the pAC (*p* \< 0.02) and that for all deviants the highest current density was in the IFG (BA47), which exhibited greater density values than the pAC across deviants (*p* \< 0.05), greater density values than all other regions for the vowel duration deviant (*p* \< 0.04), and greater density values than BA44 (*p* \< 0.04) and BA45 (*p* \< 0.03) for syllable frequency, syllable intensity and across vowel deviants.

Neural-CADSS Correlations
-------------------------

Of the three speech MMNs, which were reduced in amplitude with ketamine administration, only the syllable intensity MMN and its associated oscillatory and source activities were related to changes in subjective symptoms elicited by ketamine administration ([Figure 8](#F8){ref-type="fig"}). With respect to MMN itself, individuals with smaller Fz amplitudes during placebo experienced greater ketamine-induced increases in derealization (*r* = 0.631, *N* = 18, *p* \< 0.001) and amnesia ratings (*r* = 0.594, *N* = 18, *p* \< 0.009). As shown in [Figure 9](#F9){ref-type="fig"}, placebo theta PLF at Fz were negatively correlated with ketamine-induced increases in derealization (*r* = -0.613, *N* = 18, *p* \< 0.007) ratings.

![Scatterplots showing significant relationships between ketamine-induced changes in symptom rating (derived by subtracting placebo CADSS values from ketamine CADSS values) and baseline (placebo) intensity MMN amplitude.](fphar-10-00455-g008){#F8}

![Scatterplot showing significant relationship between ketamine-induced changes in symptom rating (derived by subtracting placebo CADSS values from ketamine CADSS values) and baseline (placebo) and theta phase locking factor (PLF).](fphar-10-00455-g009){#F9}

For the LORETA-derived ROIs ([Figure 10](#F10){ref-type="fig"}), current density in the right hemisphere pAC was inversely related to changes in amnesia (*r* = -0.612, *N* = 18, *p* \< 0.007) and derealization ratings (*r* = -0.608, *N* = 18, *p* \< 0.007) with ketamine, while current density in regions of interest of the right IFG were negatively correlated with ketamine-induced increases in self-rated derealization (BA47: *r* = -0.584, *N* = 18, *p* \< 0.01) and observer-rated psychotomimetic symptoms (BA44: *r* = -0.555, *N* = 18, *p* \< 0.017).

![Scatterplots showing significant relationships between ketamine-induced changes in symptom rating (derived by subtracting placebo CADSS values from ketamine CADSS values) and baseline (placebo) current density in LORETA-sources regions of interest.](fphar-10-00455-g010){#F10}

Discussion
==========

Summary of Findings
-------------------

The present study evaluated the hypothesis that the NMDA receptor system is critically involved in the early sensory processing of speech. As predicted, a sub-anesthetic dose of the NMDA antagonist, ketamine, significantly diminished frontal and temporal MMN generation in response to speech deviants. To our knowledge, this is the first report suggesting a causative relationship between NMDA receptor blockade and impaired speech MMN generation. The absence of ketamine effects on sensory ERP (N1) with a similar latency suggests that the reduction of speech MMNs in this study is not the result of a general weakening of ERP generators, but specifically involves neuronal processes generating the auditory MMN, including the MMN elicited by human speech. Supporting this, NMDA receptor antagonism reduced both evoked theta power and theta phase locking associated with diminished speech MMNs, and it attenuated current density in the auditory (pAC and sAC) cortex and in IFG brain regions involved in the processing and production of speech. This is consistent with previous studies showing a contributing influence of theta oscillations, and activity in temporal and frontal brain regions in the generation of the MMN. In our healthy volunteers without a history of psychopathology, speech associated neural activity assessed in the non-drug (placebo) state was negatively correlated with ketamine-induced psychotomimetic experiences, indicating that these electrophysiological markers may reflect the functional state of the NMDA receptor-mediated system and its vulnerability to disruption by receptor antagonism.

Ketamine-MMN Effects
--------------------

Though no ketamine influence was observed on MMN latency, our MMN amplitude results with speech MMNs in healthy volunteers generally conform with meta-analyses involving simple tone stimuli in humans, which show reductions in the MMN response with ketamine ([@B118]). This effect is also reported in a range of animal models, including recordings in mice ([@B140]; [@B22]), rats ([@B132]), monkeys ([@B55]; [@B32]), and also pigeons ([@B121]). Whereas in previous research ketamine's effects on MMN generated by simple acoustic stimuli were numerically but not statistically different for deviant type (i.e., ketamine tended to attenuate tone duration MMN amplitude more than frequency MMN amplitude on visual inspection alone, but this did not reach statistical significance), ketamine impairment of speech MMNs was observed across all deviant types at frontal and less so at temporal recordings. Although MMN amplitudes varied with speech deviance, the baseline (placebo) temporal MMN amplitude generally did not appear to moderate the presence of significant ketamine effects on MMN. For example, MMN in response to consonant change was significantly smaller than MMNs elicited by the other four but all were significantly affected by ketamine administration. The noticeably small consonant MMN, exhibiting no clear discernible onset/offset or peak within the typical MMN latency window, has been attributed, in previous work, to more difficult discriminability (vs. standard) based on behavioral discrimination tests ([@B61]).

Mismatch negativity is thought to consist of two main generators: one in the bilateral auditory cortex, underlying pre-perceptual sound change detection in the auditory cortex, which is thought to trigger the frontal cortex MMN generator, associated with the initiation of attention switch to sound change ([@B97]; [@B99]). Given the ketamine-induced MMN reductions at frontal and temporal recording sites and the suggestion that MMN generation involves prediction-error signaling ([@B133]), it is reasonable to speculate that in the language domain, glutamate dysregulation due to NMDA receptor hypofunction may induce problems in prediction-error generation (i.e., the MMN) in a temporo-frontal network circuit involved in early sensory processing, manifesting as diminished MMNs to speech deviants. Non-significant ketamine effects for consonant and syllable intensity deviant MMNs at temporal but not frontal cortex has potential relevance for MMN findings in schizophrenia.

Ketamine-Oscillatory Effects
----------------------------

In addition to our MMN observations using the conventional time-domain approach, we also adopted the approach of more recent human studies and utilized 'time-frequency' neuro-oscillatory analyses of electrophysiological responses as a function of underlying spectral frequency.

To our knowledge, this is the first investigation of the time-frequency signature of human MMN responses to NMDA receptor antagonist effects. Not observed with the standard stimulus, averaged evoked theta power and theta phase locking associated with speech (frequency, intensity, vowel) deviants were found to be significantly diminished by ketamine compared to placebo. Time-frequency studies have revealed the contribution of the theta frequency band in driving the neuronal generation of the MMN in frontal and temporal areas. Although this research shows that neural generation of the MMN response is accompanied by theta band power modulation and phase alignment, their individual contribution varies with deviant type ([@B83]) and their specific association with normal and abnormal sensory/cognitive processes is not clear. NMDA receptor antagonists have been found to reduce evoked theta power during MMN generation ([@B82]) and other task events in rodent models ([@B21]; [@B81]). Interestingly, speech-evoked MMN and theta power in healthy volunteers serve as predictors of behavioral speech perception at the syllable and sentence level and, along with perception accuracy are reduced during noise stress ([@B75]), which also disrupts NMDA receptor signaling ([@B16]).

Phase resetting, which refers to the systematic adjustment of the phase of ongoing oscillations to give a consistent phase relationship to a stimulus, contributes to the generation of ERPs including the MMN. Indexed by the PLF measure of inter-trial phase variability, modulation of theta phase consistency across trials of oscillatory neural activity was significantly reduced with ketamine administration. These effects, observed in relation to frequency and intensity deviants, were concurrent with ketamine-induced reduction of speech MMNs and indicate that NMDA receptor-mediated neurotransmissions and NMDA receptor hypo-function underly normal and abnormal theta phase resetting dynamics contributing to speech MMN generation in healthy volunteers, Rodent MMN and evoked theta power impaired by NMDA receptor antagonism are mitigated by concurrent treatment with the NMDA receptor agonist glycine, suggesting that MMN generation both in time (ERP) and time-frequency (neuro-oscillatory) domain analyses, may serve as effective translational measures for revealing circuit dynamics underlying acoustic deviance detection. Compared to the auditory high frequency gamma (40 Hz) response, deficits of which are associated with impaired function of rapidly firing cortical parvalbumin (PV)-type expressing inhibitory interneurons in thalamocortical circuits ([@B35]), theta frequency rhythms are linked to interactions involving more slowly firing non-PV cells, especially somatostatin-type (SST) inhibitory interneurons in cortical circuits ([@B145]).

It is of relevance to note that ketamine-induced changes in evoked theta and PLF occurred in the absence of any changes in background, ongoing theta oscillations. Analysis of baseline (pre-stimulus) and resting EEG in healthy humans administered ketamine has been mixed and have not consistently mimicked this oscillatory abnormality ([@B72]; [@B74]; [@B18]). These present findings, observed with a sub-anesthetic dose of ketamine, suggest that impaired detection of speech deviants during NMDA receptor blockade may not be dependent on alterations in tonic cortical activity.

Ketamine-Source Effects
-----------------------

Neural activity in ROIs involved in the temporofrontal network implicated in the generation of the auditory MMN elicited by speech (frequency, intensity, vowel duration) change was significantly attenuated by ketamine. Depending on deviant type, intracortical current density in both temporal and frontal cortical areas was reduced concurrently with impairments in scalp-recorded MMN and theta oscillatory responses during detection of speech deviants. Paralleling recent LORETA observations in healthy volunteers of ketamine-induced reductions in current density of auditory, cingulate and middle frontal cortical sources of tone deviant MMNs ([@B129]), our present source localization findings support a role for deficient NMDA receptor-mediated neurotransmission in hypofunction of auditory and frontal cortical generators associated with aberrant speech deviance detection in schizophrenia.

Within the predictive coding formulation of MMN generation, which accommodates the findings of multiple studies showing that there are temporal and frontal cortical sources underlying MMN generation ([@B31]), our findings of ketamine-induced reductions in speech MMNs together with current density reductions in temporal and frontal cortical regions may indicate alterations in prediction error in low level (auditory) sources and in higher cortical levels. Additionally, they may reflect changes in temporal-frontal connections that are thought to involve NMDA receptor-dependent synaptic plasticity and underly MMN generation ([@B29], [@B30]). Data from neuroimaging studies of auditory-change detection suggest that recruitment of the frontal cortex (IFG), particularly in the right hemisphere, increases with decreasing deviance. This suggests that the right IFG may engage with the auditory cortex to produce a contrast enhancing effect facilitating the detection of smaller deviances ([@B106]; [@B20]), or complex (e.g., language), ambiguous (e.g., Finnish stimuli), and difficult-to-detect stimulus changes. Although the typically observed sequential activation of these sources (auditory cortical preceding frontal) is compatible with the notion that the auditory cortical output is "evaluated" in some way by frontal regions ([@B136]) and is observed in response to large deviants, a reverse activation pattern (IFG activation before temporal) is observed with the processing of small deviants ([@B138]). Interestingly, strong evoked theta band synchronization between temporal and frontal regions is observed during auditory MMN generation ([@B45]; [@B13]).

Relevance to Schizophrenia
--------------------------

Ketamine-induced reductions in speech MMNs at frontal and temporal recordings mimic the impaired speech MMN generation observed in schizophrenia with EEG and magnetoencephalography (MEG) recordings ([@B64]; [@B63]; [@B147]; [@B67]; [@B66]; [@B24]) and directly implicate deficient NMDA receptor- dependent neurotransmission in the aberrant processing of speech in this disorder. NMDA-mediated disruption of speech processing may possibly contribute to negative symptoms (such as social withdrawal) by reducing attentional switching to socially relevant auditory cues (e.g., intensity in a speaker's voice) and/or may contribute to the phenomenology of thought-disordered speech and false perceptual influences in the language system (i.e., auditory verbal hallucinations).

These MMN effects were concurrent with ketamine-induced disruptions in evoked theta power and theta phase locking and are consistent with findings linking MMN dysfunction in chronic and first episode schizophrenia primarily to an impaired theta frequency response ([@B135]; [@B7]; [@B93]; [@B13]; [@B41]; [@B146]). It has been suggested that by diminished theta power modulation and phase resetting in response to speech stimuli, may contribute to cognitive dysfunction in schizophrenia, and may be linked to the impaired interplay between cortical pyramidal neurons and circuit SST-type GABAergic interneurons ([@B53]).

These sensor-level neuroelectric alterations with ketamine were paralleled by reductions in intra-cortical current density in frontal and temporal ROIs, cortical areas which have also been shown by either EEG ([@B42]; [@B76]; [@B113]; [@B1]; [@B131]), high-density EEG ([@B109]; [@B148]), fMRI ([@B143]; [@B69]), or LORETA sourcing ([@B90]; [@B126]; [@B28]), to be underactivated during MMN generation. Weaker frontal/temporal circuitry has also been associated with MMN reductions to speech stimuli in schizophrenia ([@B129]), and based on our findings, may implicate deficient NMDA receptor-mediated neurotransmission in underlying frontal and auditory cortical generators.

The clinical findings with ketamine in healthy volunteers were as expected, with significant dissociative effects reflected in marked increases in self-rated derealization scores, as well as by increases in amnesia and observer-rated scores. Consistently reported, and co-occurring with reductions in MMN in previous ketamine studies, these perceptual/dissociative phenomena are part of a spectrum of transient schizophrenia-like psychoactive effects (including positive and negative symptoms) produced with acute sub-anesthetic ketamine ([@B129]). Unrelated to baseline symptomatology, ketamine also exacerbates positive symptoms in schizophrenia patients in a way that is strikingly reminiscent of symptoms during active episodes of the disorder ([@B79]). Although not blocked by conventional antipsychotics such as haloperidol, and only blunted by the atypical antipsychotic clozapine ([@B88]), clinical trials with sarcosine (a glycine reuptake inhibitor) and glycine site agonists (e.g., [D]{.smallcaps}-serine) have reported beneficial effects on the negative symptoms of schizophrenia ([@B69]; [@B90]) (both glycine and glutamate binding are essential for NMDA receptor activation). Active high-dose glycine attenuates MMN in healthy humans ([@B87]) but clinical trials with [D]{.smallcaps}-serine in schizophrenia showed acute increases in duration MMN. Further, chronic (6 weeks) increases in frequency MMN were observed, as well as improvements in positive and negative symptoms, both of which were predicted by baseline MMN amplitudes (i.e., smaller amplitudes correlated with greater clinical response) ([@B59], [@B60]; [@B38]). Relatedly, glutathione deficiency also produces schizophrenia phenotypes including hypofunction of NMDA receptors ([@B124]), and administration of the glutathione precursor *N*-acetyl-cysteine (NAC) improved MMN in chronic schizophrenia ([@B80]) and in early psychosis ([@B115]).

Although not implying any risk of disorder onset in our healthy volunteers, individuals varied in their susceptibility to particular psychotomimetic symptoms induced by ketamine. Individual differences in ketamine-induced effects were strongly correlated with the magnitude of MMN in a baseline (placebo) condition, in particular with smaller amplitudes to the intensity deviant being associated with more intense psychosis-like symptoms. This finding parallels similar observations showing baseline tone duration and tone frequency MMNs correlating with the degree of psychosis-like experiences with ketamine ([@B139]). Also shown with the intensity deviant following ketamine infusion, evoked theta power and theta phase locking, as well as intracortical current density in auditory (pAC) and language-related (BA44 and BA47) brain regions at baseline were inversely correlated with the degree of psychotomimetic experiences. As with previous fMRI studies, in which activity of specific symptom changes correlated with functional alterations in distinct brain regions during ketamine infusion ([@B19]; [@B43]), selective theta oscillatory indices and regional current densities exhibited differing relationships to ketamine-induced psychotomimetic experiences, thus supporting a NMDA receptor-regulated neural basis for the varied symptoms characterizing schizophrenia. Baseline individual differences in MMN-indexed vulnerability to psychosis may reflect genetic influences on the cortical expression of glutamate receptors, which are reduced in schizophrenia ([@B12]) and have been shown to modulate tonal ([@B23]) and phonetic ([@B68]) MMN response.

As observed in earlier work ([@B125]), the degree of psychosis-like experiences evoked by NMDA receptor antagonists varies with the degree of NMDA receptor occupancy. As such, stronger psychotomimetic responses at the same dose of NMDA receptor antagonist reflect a greater disruption in NMDA receptor-dependant neurotransmission and, accordingly, the MMN has been interpreted as providing some information about the functional "condition" of NMDA receptor-dependent systems. This can be regarded as an indicator of the vulnerability or resiliency of the NMDA receptor system to acute perturbation by antagonists: a smaller MMN indicates a less resilient or less abundant NMDA receptor system, that is also more perturbed by NMDA receptor antagonist treatment ([@B139]). Similarly, speech-related MMNs and their associated theta oscillations and intracortical current densities in frontotemporal regions may serve as neural indicators of the functional state of NMDA receptor-mediated neurotransmission and may be useful neuroelectric tools in studies of normal and abnormal NMDA receptor functioning in humans.

The reasons why these relationships between baseline (placebo) electrophysiology and symptom changes with ketamine were limited to detection of syllable intensity deviants are not clear. Impaired sensitivity to changes in pitch and duration ([@B134]; [@B34]) processes known to localize to the primary auditory cortex ([@B137]), along with deficits in sensitivity to modulation of intensity discrimination are frequently observed in schizophrenia ([@B5]). In studies of auditory emotion recognition, patients have also shown relatively greater deficit in the ability to use pitch-based versus absolute intensity-based features of speech ([@B84]; [@B34]). Although it is difficult to compare the degree of change across speech deviants in our study, acoustic/vocal stimuli with high cue saliency tend to increase temporal cortex activation and associated sensory-integrative functions, while with ambiguous, low salience speech stimuli, greater evaluative processes associated with inferior temporal regions are recruited ([@B85]). It is possible that our baseline MMN-ketamine response associations seen with intensity deviants may reflect the unique cortical recruitment pattern specific to changes in speech intensity and its disruption by NMDA receptor hypofunction.

Limitations
===========

These results provide potential insight into some of the neural mechanisms underlying NMDA receptor-mediated impairments in the sensory processing of human speech, but there are limitations to the study. The participant sample was limited to young, adult (English-speaking) healthy male volunteers, who tend to exhibit greater acute vulnerability (vs. females) to some of the behavioral effects of ketamine ([@B95]), and thus the findings do not necessarily translate to schizophrenia patients who develop NMDA receptor adaptation with increasing chronicity. Also, although their age range (early twenties) is comparable to the typical age of onset of schizophrenia, findings may not translate for speech processing in chronic patients. New language-specific neural representations (indexed by MMN) can evolve for non-native speech categories ([@B128]), and although the MMN was elicited within an optimal paradigm which allowed for neural profiling across different speech features, they were recorded in response to deviations in Finnish-language speech sounds and similar studies relevant to the native language (English) of the test subjects are required. Subjective effects of ketamine were evaluated with an instrument emphasizing perceptual/dissociative symptoms and did not address the positive, negative or cognitive symptomatology that characterizes schizophrenia. Ketamine was administered as a single dose, with no attempt to examine dose- or time-response variations, and the design lacked an active comparator drug (e.g., midazolam) which may allow for the assessment of non-specific behavior (e.g., drowsiness), and effects unrelated to NMDA receptor blockade. Examination of EEG oscillations was limited to theta frequencies and future studies need to assess a more complete frequency spectrum from slow delta to fast gamma rhythms. Although gamma band oscillations have also been associated with depression and fast-acting antidepressants like ketamine ([@B26]), they have been frequently associated with the pathophysiology of schizophrenia and associated auditory evoked response deficits ([@B17]). Moreover, relative to standard sounds, deviant sounds elicit a cascade of oscillatory modulations (beginning with gamma and followed by beta, both of which are coupled with theta) that are altered by acute ketamine administration ([@B33]; [@B122]). Further, EEG source localization lacks the spatial sensitivity of other imaging methodologies such as fMRI and was limited to specific regions of interest in the temporal and inferior frontal cortex, thus, it did not include examination of a possible role for other circuits (e.g., thalamocortical and limbic) involved in sensory processing. Although the NMDA receptor is known to specifically influence activity in the central auditory system ([@B142]) and frontal/limbic and cingulate regions ([@B141]; [@B78]; [@B105]), it is also thought to participate in widespread suppression and activation of circuit-level neural activity ([@B25]). Combining EEG and other imaging tools in a ketamine model and assessing activity and connectivity within and between multiple neural networks during stimulus-evoked and resting-state conditions may be a useful approach in future studies for delineating extrinsic and intrinsic neural factors mediating region-specific underpinnings of NMDA receptor-dependent speech/language deficits pertaining to schizophrenia and associated auditory hallucinatory experiences ([@B104]; [@B102]; [@B103]; [@B2]).

Conclusion
==========

To the best of our knowledge, this is the first study assessing the effects of the NMDA receptor antagonist ketamine on speech MMNs, and their associated oscillatory activities and intra-cortical current densities in healthy humans. Reductions in MMN generation and related neural activity across speech deviants indicates a general impairment in the processing of deviant speech. Together with the emergence of perceptual/dissociative symptoms, these findings generally support a glutamatergic/NMDA receptor model of schizophrenia and of language impairment in schizophrenia in particular. In this non-psychopathological sample, baseline (placebo) MMN, theta oscillations and current density in frontotemporal regions were associated with symptom response to ketamine and may serve as objective indicators of the functional state of NMDA receptor-mediated neurotransmission.
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